A clinical study published in the New England Journal of Medicine in 2024 (4) showed that, in people with excess fatty liver with mild to moderate fibrosis , administration of semaglutide once a week for 240 weeks was correlated with: improvement in liver composition and inflammation without worsening of fibrosis in more than 60% of cases, compared with approximately 34% of subjects on placebo reduction in scar tissue without worsening of steatohepatitis in more than 36% of patients, compared with around 22% of those on placebo resolution of steatohepatitis with a reduction in fibrosis in 32.7% of patients, compared with 16.1% in the placebo group average reduction in body weight of 10.5%, compared with just 2.0% on placebo The mechanisms that could explain these results From a medical point of view, these effects on liver health could be explained by several complementary mechanisms: a general reduction in body fat , particularly visceral fat in the abdomen and liver, a criterion often associated with improvements in liver parameters (5) a reduction in oxidative stress , known to damage liver cells (6) Although potentially interesting for supporting liver function , GLP-1 agonists are drug treatments that can have side effects (7)
In this state, the liver converts fatty acids into ketone bodies (beta-hydroxybutyrate, acetoacetate, and acetone), which serve as an alternative energy source for the brain, heart, and muscles
Heffron explains, but we know that it leads, at least transiently, to a rise in blood levels of GLP-1
Clinical trials for Mounjaro did not show burping or sulfur burps as common side effects
Not only are the products themselves questionable, but so are the business dealings of the companies peddling them.
Usually these folks are not GSH allergic, but the pathways need to be clear first
